Difference between revisions of "Risperidone LA-Paliperidone ER"

From Psychiatrienet
Jump to: navigation, search
 
(3 intermediate revisions by the same user not shown)
Line 5: Line 5:
 
| to = Paliperidone LA
 
| to = Paliperidone LA
 
| stop = {{Lastinjection}}
 
| stop = {{Lastinjection}}
| start = {{StartDepot}}
+
| start = Start depot according to general dosing advice without loading dose on the day you would normally have injected the next depot. Administer monthly.
 
| info = {{caveQT}}
 
| info = {{caveQT}}
 
| view = StopDepotStartArip.jpg
 
| view = StopDepotStartArip.jpg
 
}}
 
}}

Latest revision as of 17:05, 18 March 2022

* This switch is intended for paliperidone long acting (Xeplion®, 30 days)

Risperidone
long acting
Type Antipsychotic
Group Atypical AP
links
Medscape Risperidone
PubChem 5073
PubMed Risperidone
Kompas (Dutch) Risperidone
Wikipedia Risperidone
Paliperidone
long acting
Type Antipsychotic
Group Atypical AP
links
Medscape Paliperidone
PubChem 23724979
PubMed Paliperidone
Kompas (Dutch) Paliperidone
Wikipedia Paliperidone

Switch medication from Risperidone LA to Paliperidone LA.[1] [2]

Nietinrijdenbord.png Stop Risperidone LA
  • Day 1: Last depot injection
Eenrichtingbord.png Start Paliperidone LA

Start depot according to general dosing advice without loading dose on the day you would normally have injected the next depot. Administer monthly.

Infobord.png More information
  • During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
  • There is a possibility of QT interval prolongation.[3]
    StopDepotStartArip.jpg
Nietinrijdenbord.png — Risperidone LA
Eenrichtingbord.png — Paliperidone LA


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.